Overview of Cancer Drugs That Cause Fingerprint Loss

Year 2023, Volume: 2 Issue: 3, 127 - 140, 30.11.2023

Sara Öğretici Oral , Egemen Dere

https://doi.org/10.59312/ebshealth.1376750

Abstract

Purpose: Today, cancer; It is attempted to be treated using methods such as surgical methods, chemotherapy, radiotherapy, bone marrow, stem cell transplantation, immunotherapy, hormone and antibody therapy. Each method has its own advantages and disadvantages. One of the side effects caused by chemotherapeutic drugs is that they cause redness, swelling, itching and numbness in the hands and feet of patients. Especially during this side effect process, the loss of fingerprints causes important criminal problems. In this study, cancer drugs that cause hand-foot syndrome were examined and their effects were tried to be explained.
Material method: Articles, electronic books, journals and theses were examined through different databases.
Findings and results: In the study, the active substances of the drugs used in chemotherapy, which cause redness in the palmar and plantar regions and cause burning and sensation in the hands and feet, are presented in tables. These substances include, primarily capecitabine, cabozantinib, pazopanib, vemurafenib, axitinib, doxorubicin, sunitinib, regorafenib, docetaxel and sorafenib. The metabolic pathway that causes hand-foot syndrome is still unexplained.

Keywords

Capecitabine, 5-fluorouracil, cancer, fingerprint, hand-foot syndrome

Project Number

YOK

Parmak İzi Kaybına Neden Olan Kanser İlaçlarına Genel Bakış

Abstract

Amaç: Günümüzde kanser; cerrahi yöntemler, kemoterapi, radyoterapi, kemik iliği, kök hücre nakli, immünoterapi, hormon ve antikor tedavisi gibi yöntemler kullanılarak tedavi edilmeye çalışılmaktadır. Her yöntemin kendi içinde avantaj ve dezavantajları vardır. Kemoterapide kullanılan ilaçların meydana getirdiği yan etkilerden birisi de hastalarda el ve ayaklarda kızarıklık, şişme, kaşıntı ve hissisleşmeye neden olmasıdır. Özellikle bu yan etki sürecinde parmak izlerinin kaybolması kriminal açıdan önemli sorunlara neden olmaktadır. Bu çalışmada el ayak sendromuna neden olan kanser ilaçları incelenmiş ve etkileri açıklanmaya çalışılmıştır.
Yöntem: Farklı veri tabanları üzerinden makaleler, elektronik kitaplar, dergiler, tezler incelenmiştir.
Bulgular ve Sonuç: Çalışmada kemoterapide kullanılan ilaçlardan palmar ve plantar bölgelerde kızarıklıklara neden olan el ve ayaklarda yanma, hissislik meydana getiren ilaç etkin maddeleri tablolar halinde sunulmuştur. Bu maddeler arasında başta kapesitabin olmak üzere, kabozantinib, pazopanib, vemurafenib, aksitinib, doksorubisin, sunitinib, regorafenib, dosetaksel ve sorafenib gibi maddeler bulunmaktadır. El ayak sendromuna neden olan metabolik yol hala açıklanmamıştır.

Keywords

Kapesitabin, 5-florourasil, kanser, parmak izi, el ayak sendromu

Ethical Statement

YOK

Supporting Institution

YOK

Project Number

YOK

References

• Al-Ahval M. S. (2012) Chemotherapy and fingerprint loss: Beyond cosmetic. Oncologist. 17:(2) 291-293. doi:10.1634/theoncologist.2011-0243
• Arai, H., Battaglin, F., Wang, J., Lo, J.H., Soni, S., Zhang, W. & Lenz, H.J., (2019). Molecular insight of regorafenib treatment for colorectal cancer. Cancer Treatment Reviews 81, 101912, doi:10.1016/j.ctrv.2019.101912
• Ashrafizadeh, M., Mirzaei, S., Hashemi, F., Zarrabi, A., Zobalian, A., Saleki, H…, Samarghandian, S. (2021). New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities. Biomedicine & Pharmacotherapy, 141, doi:10.1016/j.biopha.2021.11182412
• Aslam, M.S., Naveed, S., Ahmed, A., Abbas, Z., Gull, I., Athar, M.A. (2014). Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. Journal of Cancer Therapy, 5, 817-822. doi.org/10.4236/jct.2014.58089
• Assessment-report, (2022) Vyxeos liposomal. European Medicines Agency, Science Mediciines Health, 1-96 EMA/665588/2022.
• Azadeh, P., Dashti-Khavidaki, S., Joibari A.Y., Sarbaz, S. (2017). Fingerprint changes among cancer patients treated with paclitaxel. 143:(4), 1-9 doi: 10.1007/s00432-016-2314-1
• Baer, M. R., King, L. E. & Wolff, S. N., (1985). Cytarabine-induced palmar-plantar erythema. Annals of Internal Medicine, 102(4): 556, doi:10.7326/0003-4819-102-4-556_1
• Baskın, Y. ve Çalıbaşı, G. (2011). Kanser hastalarında farmakogenetik uygulamaları ve farmakoekonomi. Türk Hijyen ve Deneysel Biyoloji Dergisi, 68 (3): 152 – 164, doi:10.5505/TurkHijyen.2011.77598
• Battistella, M., Fremont, G., Vignon-Pennamen, M. D., Gornet, J. M., Dubertret, L. & Viguier, M. (2008). Imatinib-ınduced hand-foot syndrome in a patient with metastatic gastrointestinal stromal tumor. Archives of Dermatology, 44(10):1400-1402, doi:10.1001/archderm.144.10.1400
• Boogaard, W.C.V.D., Komninos D.S.J., Vermeij W.P. (2022). Chemotherapy side-effects: Not all DNA damage is equal. Cancers, 14, 627. doi:10.3390/cancers14030627
• Brose, R. D., Lehrmann, E., Zhang, Y., Reeves, R. H., Smith, K. D. & Mattson, M. P. (2018). Hydroxyurea attenuates oxidative, metabolic, and excitotoxic stress in rat hippocampal neurons and improves spatial memory in a mouse model of Alzheimer's disease. Neurobiology of Aging, 72: 121-133, doi:10.1016/j.neurobiolaging.2018.08.021.
• Butler, D., Nambudiri, V. E. & Nandi, T. (2014). Hydroxyurea-associated acral erythema in a patient with polycythemia vera. American Journal of Hematology, 89:9, 865-940, doi:10.1002/ajh.23698
• Caronia, D., Martin, M., Sastre, J., Torre, J. D. L., Garcia- Saenz, J. A., Alonso, M. R…, & Gonzalez-Neira, A. (2011). A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-ınduced hand-foot syndrome. Clinical Cancer Research, 17 (7), doi:10.1158/1078-0432.CCR-10-1741
• Carr, C., Ng, J., &Wigmore, T. (2008). The side effects of chemotherapeutic agents. Current Anaesthesia & Critical Care 19:(2), 70-79. doi:10.1016/j.cacc.2008.01.004
• Cersosimo, R. J. & Hong, W.K., (1986). Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. Journal of Clinical Oncology 4(3) 425-439, doi:10.1200/JCO.1986.4.3.425
• Chockaian, K., Vayanaperumal, R. & Kanagaraj, B.R. (2013). New approach for ıdentifying hereditary relation using primary fingerprint patterns. The Institution of Engineering and Technology, 7(5), 423-431, doi:10.1049/iet-ipr.2012.0399
• Choueiri, T.K., Powles, T., Burotto, M., Escudier, B., Bourlon, M.T., Zurawski, B…, & Motzer, R.J. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 384;9, doi:10.1056/NEJMoa2026982
• Chu, E. ve Sartorelli, A.C. (2014). Kanser kemoterapisi, Temel ve klinik farmakoloji 12. Baskı, 949-975, Nobel Tıp Kitabevi.
• Cohen, M. H., Dagher, R., Griebel, D.J., Ibrahim, A., Martin, A., Scher, N.S…, & Pazdur, R. (2002). U.S. food and drug administration drug approval summaries: ımatinib mesylate, mesna tablets, and zoledronic acid. The Oncologist 7: 393-400, doi:10.1634/theoncologist.7-5-393
• Cohen, P., Cross, D. & Janne, P.A. (2021). Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery 20, 551-569, doi:10.1038/s41573-021-00195-4
• Correia, A., Silva, D., Correia, A., Vilanova, M., Gärtner, F., & Vale, N. (2018). Study of new therapeutic strategies to combat breast cancer using drug combinations. Biomolecules, 8(4); 175, doi:org/10.3390/biom8040175
• Cummins H. & Midlo C. (1926). Palmar and plantar epidermal ridge configurations (dermatoglyphics) in european- americans. American Journal of Biological Antropology, 9(4), 471-502. doi:10.1002/ajpa.1330090422
• Çetin, D.A., Gündeş, E., Aday, U., Çiyiltepe, H., Değer, K.C., & Duman, M. (2016). Metastatik kolon kanseri tedavisinde bevacizumab sonrası ince barsak perforasyonu: Nadir bir olgu. Dicle Tıp Dergisi 43 (1), 168-170, doi:10.5798/diclemedj.0921.2016.01.0661
• Daldal, Y. D. ve Demiralay, E. Ç. (2020). Merkezi kompozit dizayn kullanılarak kapesitabin tayini için RPLC yönteminin geliştirilmesi ve validasyonu. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi Cilt 24(1), 105-112, doi:10.19113/sdufenbed.582980.
• Degen, A., Alter, M., Schenck, F., Satzger, I., Völker, B., Kappa, A., & Gutzmer, R. (2010). The hand-foot-syndrome associated with medical tumor therapy – classification and management. Journal der Deutschen Dermatologischen Gesellschaft 8(9), 652- 661, doi:10.1111/j.1610-0387.2010.07449.x
• Demirdağ, H. G., Ayanoğlu, B. T., & Armağan, B. Y. (2019). El-ayak sendromu ve el-ayak deri reaksiyonunun olgu serisi ile değerlendirilmesi. Turkderm-Deri hastalıkları ve Frengi Arşivi Dergisi 53, 28-31, doi:10.4274/turkderm.galenos.2018.98624.
• Demirkan, S., Gündüz, Ö., & Devrim, T. (2017). Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol. Journal of the American Academy of Dermatology, Case Reports, 20;3(4), 354-357, doi:10.1016/j.jdcr.2017.03.017
• Doorn, L.V., Veelenturf, S., Binkhorest, L., Bins, S., & Mahhijssen, R. (2016) Capecitabine and the risk of fingerprint loss. Jama Oncology 3(1), 122-123, doi:10.1001/jamaoncol.2016.2638
• Ekinci P.A., Erbudak E, & Baykal C. (2013) 2012 yılı Haziran ayında İstanbul'da elayak-ağız hastalığı sıklığında önemli artış. Türkderm, 47:192-3, doi:10.4274/turkderm.19942
• Escudier, B. & Gore, M., (2011). Axitinib for the management of metastatic renal cell carcinoma. Drugs R D, 11 (2), 113-126, doi:10.2165/11591240-000000000-00000.
• Ferreira, M. N., Ramseier, J., & Leventhal, J.S. (2019) Dermatologic conditions in women receiving systemic cancer therapy. International Journal of Womans Dermatology, 7;5(5), 285-307 doi:10.1016/j.ijwd.2019.10.003.
• Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O.L. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future Outlook. Cancer Treatment Reviews 86, doi:10.1016/j.ctrv.2020.102017
• Giacchero, D., Monpoux, F., Chiaverini, C., & Lacour, J.P. (2008). Syndrome mains-pieds secondaire à la prise de 6-mercaptopurine chez un enfant de quatre ans. Annales de dermatologie et de vénéréologie, 135, 580-583, doi:10.1016/j.annder.2008.02.021
• Giverhaug, T., Loennechen, T., & Aarbakke, J. (1999). The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX). General Pharmacology 33, 341–346, doi:10.1016/S0306-3623(99)00022-1
• Glover, J. D., Li, J., Zhang, H., Jin, L., Headon, D. J., & Wang, S. (2022). Limb development genes underlie variation in human fingerprint patterns. Cell 185(1), 95–112, doi:10.1016/j.cell.2021.12.008
• Gökçe, Ö., Yılmaz, A., Gürbüz, V., Konaç, E, & Ekmekçi, A. (2011). İnsan servikal kanser hela hücrelerinde vinorelbin’in apoptotik etkisi. Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi 25(1), 5-14, https://dergipark.org.tr/tr/pub/deutip/issue/4659/63487#article_cite
• Grinnell, M., Rieger, K. E., Katsumoto, T. R., Kwong, B. Y., & Zaba, L.C. (2020). Anti-cancer therapy related hand-foot syndrome in patients with systemic sclerosis: Case series and literature review. Current Problems in Cancer: Case Reports 1, doi:10.1016/j.cpccr.2020.100021
• Gutierez, S. B., Lucenario, J. L. S., & Yebes, M. J. T. (2012). Dermatoglyphic studies among the dumagat-remontado tribal population of the philippines. Journal of Anthropology 12, 1-6, doi:10.1155/2012/812128
• Gürkan-Alp, A. S. & Bozca, F. (2019). Tirozin kinaz enzim inhibitörü yeni bileşikler ve yapı aktivite ilişkilerinin değerlendirilmesi. FABAD Journal of Pharmaceutical Sciences, 44:(1) 65-78.
• Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase ıı ınhibitor. European Journal of Cancer 34(10), 1514-1521, doi:10.1016/s0959-8049(98)00228-7.
• Innocenti, F., Iyer, L., Ramirez, C., Green, M. D., & Ratain, M. J. (2001). Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metabolism and Disposition, 29 (5) 686-692, https://pubmed.ncbi.nlm.nih.gov/11302935/
• Jacobi, U., Waibler, E., Schulze, P., Sehouli, J., Oskay-Özcelik, G., Schmook, T…, . Lademann, J. (2005). Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Annals of Oncology, 16(7), 1210-1211. doi:10.1093/annonc/mdi204
• Jordan, K., Kellner, O., Kegel, T., Schmoll, H. J., & Grothey, A. (2004). Phase II trial of capecitabine/ırinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clinical Colorectal Cancer, 4(1), 46-50, doi:10.3816/ccc.2004.n.009
• Kanchan, T. & Krishan, K. (2018). Loss of fingerprints: forensic implications. Egyptian Journal of Forensic Sciences 8(19), doi:10.1186/s41935-018-0051-0
• Kurtan, M., Kurtoğlu, S., & Melikoğlu, G., (2014). Kamptotesin. Marmara Pharmaceutical Journal 18, 85-100, doi:10.12991/mpj.2014186125
• Lacouture, M. E., Reilly, L. M., Gerami, P., & Guitart, J. (2008). Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Annals of Oncology, 19 (11), 1955–1961, doi:10.1093/annonc/mdn389
• Lou, Y., Wang, Q., Zhemg, J., Hu, H., Liu, L., Hong, D., & Zeng, S. (2016). Possible pathways of capecitabine-ınduced hand-foot syndrome. Chemical Research in Toxicology, 29, 1591-160, doi:10.1021/acs.chemrestox.6b00215
• Marigny, K., Aubin, F., Burgot, G., Gall, E. L., & Gandemer, V. (2005). Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer Chemother Pharmacol, 55(3), 244–250, doi:10.1007/s00280-004-0858-2.
• McLellan, B., Ciardiello, F., Lacouture, M. S., Segaert, S., & Cutsem, E. V. (2017). Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management. Annals of Oncology, 26, 2017-2026, doi:10.1093/annonc/mdv244
• MFMER (2023). Vinorelbine (Intravenous Route). 1998-2023 Mayo foundation for medical education and research. https://www.mayoclinic.org/drugs-supplements/vinorelbine-intravenous-route/side-effects/drg-20066710?p=1
• Milano, G., Grimaldi, M., Mari, M., Lassalle, S., Formento, J., Froncoual, M…, & Hofman, P. (2008). Candidate mechanisms for capecitabine- related hand- foot syndorme. British Journal of Clinical Pharmacology, 88-95, doi:10.1111/j.1365-2125.20008.03159.x
• Mross, K., Frost, A., Steinbild, S., Hedbom, S., Büchert, M., Fsol, U…, & Christensen, O. (2012). A phase I dose–escalation study of regorafenib (bay 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clinical Cancer Research, 18(9), 2658-2667, doi:10.1158/1078-0432.CCR-11-1900
• Munehiro, A., Yoneda, K., Nakai, K., Demitsu, T., Moriue, T., Moriue, J…, & Kubota, Y. (2010). Bevacizumab-induced hand-foot syndrome: circumscribed type. British Journal of Dermatology 162, 1395-1416, doi:10.1111/j.1365-2133.2010.09716.x
• Musialek, M.W. & Rybaczek, D. (2021). Hydroxyurea-the good, the bad and the ugly. Genes, 12(7), 1096, doi:10.3390/genes12071096
• Nardi, A.E., Sancassiani, F., Barru V., Kalcev G., Uras V., Meloni G..., & Carta M.G. (2023) The effects of tyrosine kinase inhibitors (TKIs in monotherapy and with addon treatments on health-related quality of life of people with chronic myeloid leukemia: a systematic review of randomized-controlled trials. Clinical Practice & Epidemiology in Mental Health, 19 (1,M2), doi:10.2174/17450179-v17-e211118-2021-HT2-1910-12
• Natu, A., Pedgaonkar, A., & Gupta, S. (2023). Mitochondrial dysfunction and chromatin changes with autophagymediated survival in doxorubicin resistant cancer cell lines. Biochemical and Biophysical Research Communications 648, 1-10, doi:10.1016/j.bbrc.2023.01.081
• Nguyen, L., Chapel, S., Tran, B.D., & Lacy, S. (2019). Cabozantinib exposure–response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. Journal Pharmacokinet Pharmacodyn, 46, 577-589, doi:10.1007/s10928-019-09659-y
• Noesbeck, J., Burger, B., Fuchs-Telem, D., Pavlovsky, M., Fenig, S., Sarig, O…, & Sprecher, E. (2011) A mutation in a skin specific isoform of SMARCAD1 causes autosomal-dominant adermatoglyfhia. The American Journal of Human Genetics 89(2), 302-307, https://core.ac.uk/download/pdf/82214524.pdf
• O'Brien, M. E. (2008). Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anti Cancer Drugs 19(1), 1-7, doi:10.1097/CAD.0b013e3282f14a00
• Ogino, M. H. & Tadi, P. (2023) Cyclophosphamide. StatPearls, last update 3 july, https://www.ncbi.nlm.nih.gov/books/NBK553087/
• Okajima, M. (1975). Development of dermal ridges in the fetus. Journal of Medical Genetics 12, 243, doi:10.1136/jmg.12.3.243
• Osoro, I., Sharma, A., Amir, M., Vohra, M., Kumar. R., Kumar, H…, & Bangar, H. (2022). Prevention and management of anthracycline induced cardiotoxicity: A review. Health Sciences Review 5, doi:10.1016/j.hsr.2022.100070
• Ölgen, S. & Şentürk, A. M. (2021). Tirozin kinaz inhibitörü bileşiklerin tasarımı ve antikanser etki mekanizmaları. FABAD Journal of Pharmaceutical Sciences 46, 2, 159-178, https://dergi.fabad.org.tr/pdf/volum46/Issue2/159-178.pdf
• Öneç, B. (2016). Sitozin arabinozid (ARA-C) ilişkili nörotoksisite. Turkiye Klinikleri Journal Hematology-Special Topics 9(3),110-113, https://www.turkiyeklinikleri.com/article/tr-sitozin-arabinozid-ara-c-iliskili-norotoksisite-75875.html
• Pajk, B., Cufer, T., Canney, P., Ellis, P., Cameron, D., Blot, E…, & Piccart, M. (2008). Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial. The Breast 17, 180–185, doi:10.1016/j.breast.2007.09.002
• Paludetto, M. N., Puisset, F., Le Louedec, F., Allal, B., Lafont, T., Chatelut, E., & Arellano, C. (2018). Simultaneous monitoring of pazopanib and its metabolites by UPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 154, 373-383, doi:10.1016/j.jpba.2018.03.013.
• Pemovska, T., Johnson, E., Kontro, M., Repasky, G.A., Chen, J., Wells, P…, & Wennerberg, K. (2015). Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519(7541), 102-105, doi:10.1038/nature14119. Epub 2015 Feb 9.
• Petridis, G. & Üner, B. (2020). Parmak izlerinden elde edilen DNA’nın mini STR tekniği ile incelenmesi. Journal of Medical Sciences, 1(5) 46-58, doi:10.46629/JMS.2020.28
• Pick, A. M. & Neytsrom, K. K. (2012). Pazopanib for the treatment of metastatic renal cell carcinoma. Clinical Therapeutics, 34(3), 511-520, doi:10.1016/j.clinthera.2012.01.014
• Razis, E., Karina, M., Karanastassi, S., & Fountzilas, G. (2006). Three case reports of hand-foot syndrome with gefitinib. Canser Investigation 26(5), 514-516, doi:10.1080/07357900600814847
• Sabuncuoğlu, S. & Özgüneş, H. (2011). Sisplatin toksisitesi: Oksidatif stresin önemi ve antioksidanların etkisi. İstanbul Tıp Fakültesi Dergisi, 74(1), 18-25, https://dergipark.org.tr/tr/pub/iuitfd/issue/9264/115877
• Saied, M., Ali, K., & Mosayeb, A., (2023). Rosemary (Rosmarinus officinalis L.) essential oil alleviates testis failure induced by Etoposide in male rats. Tissue and Cell 81, 102016, doi:10.1016/j.tice.2023.102016
• Saji, S., Toi, M., Morita, S., Iwata, H., Ito, Y., Ohno, S..., & Sakamoto, J. (2007). Dose-finding phase I and pharmacokinetic study of capecitabine (xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with ınoperable or metastatic breast cancer. Oncology, 72, 330–337, doi:10.1159/000113062
• Sennino, B., Oonuma, T. I., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V…, & McDonald, D.M. (2012). Suppression of tumor ınvasion and metastasis by concurrent ınhibition of c-met and VEGF signaling in pancreatic neuroendocrine tumors. American Assosiation for Canser Research, 2(3), 270-287, doi:10.1158/2159-8290.CD-11-0240
• Singh, A. & Xu, Y.J., (2016). The cell killing mechanisms of hydroxyurea. Genes 7(11), 99, doi:10.3390/genes7110099
• Su, M. H., Chen, G. Y., Lin, J. H., Lee, H. H., Chung, K. C., & Wang, P.H. (2019). Paclitaxel-related dermatological problems: Not only alopecia occurs. Taiwanese Journal of Obstetrics & Gynecology 58, 877-879, doi:10.1016/j.tjog.2019.08.003
• Sunakawa, Y., Furuse, J., Okusaka, T., Ikeda, M., Nagashima, F., Ueno, H…, & Sasaki, Y. (2014). Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs, 32: 104-112, doi:10.1007/s10637-013-9953-8
• Tang, W., Chen, Z., Zhang, W., Cheng, Y., Zhang, B., Wu, F…, & Wang, X. (2020). The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduction and Targeted Therapy 5, 87, doi:10.1038/s41392-020-0187-x
• Tuğlu, M. M. & Melli, M. (2012). İmatinib: Etki mekanizması ve direnç geliștirme mekanizmaları. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 65(2), doi:10.1501/Tıpfak_000000813
• Turaçlı, İ. D. (2017). Malign melanom oluşum ve ilerleme sürecinde gözlenen bazı moleküler değişimler. Turk Journal Dermatology, 11, 184-188, doi:10.4274/tdd.3000
• Vance, S.L., Singer, H.M., Silvers, D., Husain, S., & Kabigting, F. (2017). Delayed-onset vemurafenib-induced panniculitis. Case Reports, 3, 384-386, doi:10.1016/j.jdcr.2017.06.001
• Waller, C.F. (2018). Imatinib mesylate. Small Molecules in Hematology 212, 1-27, doi:10.1007/978-3-319-91439-8_1
• Wen, C., Li, Y., Huang, Y., Wang, N., He, S., Bao, M…, & Wu, L. (2023). CircSETD3 mediates acquired resistance to gefitinib in non-small lung cancer cells by FXR1/ECT2 pathway. International Journal of Biochemistry and Cell Biology 154, doi:10.1016/j.biocel.2022.106344
• Xiao, J., Yuan, L., Wang, J., Hao, L., & Wang, D. (2019). Study on the mechanism and intervention strategy of sunitinib induced nephrotoxicity. European Journal of Pharmacology 864, 172709 doi:10.1016/j.ejphar.2019.172709.
• Xu, Y., Jiang, Y., & Chen, X. (2022). Mechanisms underlying paclitaxel-induced neuropathic pain: Channels, inflammation and immune regulations. European Journal of Pharmacology 933, 175288 doi:10.1016/j.ejphar.2022.175288
• Yoshida, Y., Sasaoka, S., Tanaka, M., Matsumoto, K., Inoue, M., Satake, R…, & Nkamura, M. (2022). Analysis of drug-induced hand–foot syndrome using a spontaneous reporting system database. Therapeutic Advances in Drug Safety,13, doi:10.1177/20420986221101963.
• Zhao, J., Zhang, X., Cui, X., Wang, D., Zhang, B., & Ban, L. (2020). Loss of fingerprints as a side effect of capecitabine therapy: Case report and literature review. Oncology Research, 258, 103-106, doi:10.3727/096504019X15605078731913
• Zhu, L. & Chen, L. (2019). Progress in research on paclitaxel and tumor immunotherapy. Cellular & Molecular Biology Letters, 2-11, doi:10.1186/s11658-019-0164-y
• Zühlke, R. L. (1974). Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica, 148, 90-92, doi:10.1159/000251603